Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the ...

and diabetic retinopathy, while the 2 mg injection is approved for wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic ...

AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

The National Electronics and Computer Technology Center (Nectec), the Department of Medical Services and Mahidol University and alliances have introduced a Medical AI Data Platform for data sharing ...

Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ((sBLA)) for Eylea HD injection, 8 mg, to treat macular ...